CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-23). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1561 · Search date 2026-07-23 · Methodology v0.6

Exercise-based cardiac rehabilitation,
does it really help with Reduced recurrent myocardial infarction and hospitalisation in people with coronary heart disease?

30-Second Summary
A
Evidence Grade A · 88 · Safety unknown
Recurrent myocardial infarction has high-certainty evidence, while reduced all-cause admission has moderate-certainty evidence
What the
research shows
Exercise-based cardiac rehabilitation is rated A because direct hard-endpoint evidence for reducing recurrent myocardial infarction in coronary heart disease is of high certainty. The 2021 Cochrane review included 85 randomized trials; fatal or nonfatal myocardial infarction at 6 to 12 months had an RR of 0.72 (95% CI 0.55 to 0.93; 22 trials, 7,423 participants) with high certainty. All-cause hospital admission at the same time point had an RR of 0.58 (95% CI 0.43 to 0.77; 14 trials, 2,030 participants) with moderate certainty, whereas all-cause mortality had an RR of 0.87 (95% CI 0.73 to 1.04) with moderate certainty and included no effect.
What the
ads claim
Promotional language can recast the intervention as simple fitness training or a cure for heart disease. The studied intervention was a structured healthcare program combining risk assessment, prescribed exercise, education, and behavioral support; it is distinct from medicines, automated external defibrillators, and acute myocardial-infarction treatment.
*

Useful facts when choosing a product

  • Exercise-based cardiac rehabilitation is not a single exercise product; it is a structured healthcare program that includes assessment, prescribed aerobic or resistance exercise, risk-factor education, and behavioral support.
  • Programs in the Cochrane review were delivered in hospital, community, and home settings and used exercise alone or exercise combined with education or psychological support.
  • Exercise intensity and supervision are adjusted after assessment of ischemia, arrhythmia, heart failure, postoperative status, and functional capacity.
  • Serious events during exercise are uncommon, but people with chest pain, syncope, severe dyspnea, or arrhythmia risk require clinical assessment and appropriate supervision.
Gap Measurement · Verdict 1561 · A 88
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2021 Dibben Cochrane review included 85 randomized trials comparing exercise alone or exercise combined with educational or psychological components against a no-exercise control in adults with coronary heart disease. At 6 to 12 months, myocardial infarction was reduced across 22 trials and 7,423 participants, RR 0.72, with an NNTB of 75 (95% CI 47 to 298) and high GRADE certainty. All-cause admission was reduced across 14 trials and 2,030 participants, RR 0.58, NNTB 12 (95% CI 9 to 21), with moderate certainty after downgrading for suspected publication bias. All-cause mortality across 25 trials and 8,823 participants had an RR of 0.87 (95% CI 0.73 to 1.04) with moderate certainty. A 2023 European Heart Journal meta-analysis of the same 85-trial evidence base reported pooled RRs of 0.82 for myocardial infarction, 0.77 for hospitalisation, and 0.96 for all-cause mortality across follow-up.

02

Why this is classified as A (88)

The core adjudicated endpoint, fatal or nonfatal myocardial infarction at 6 to 12 months, was reduced with RR 0.72 (95% CI 0.55 to 0.93) across 22 trials and 7,423 participants with high GRADE certainty, while all-cause admission was also reduced with moderate certainty, giving A with 88 points.

Counterpoint. Effect sizes and statistical certainty differed for all-cause mortality and longer follow-up, so the high certainty for short-term myocardial infarction was not transferred to every mortality or long-term endpoint.

Rejudgment record. New verdict — The myocardial-infarction endpoint specified in the claim has high GRADE certainty across multiple randomized trials and the all-cause admission endpoint has moderate certainty, meeting the direct hard-endpoint rule for grade A

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced recurrent myocardial infarctionAAt 6 to 12 months, RR was 0.72 (95% CI 0.55 to 0.93) across 22 trials and 7,423 participants, with high GRADE certainty.
Reduced all-cause hospital admissionBAt 6 to 12 months, RR was 0.58 (95% CI 0.43 to 0.77) across 14 trials and 2,030 participants, with moderate certainty after downgrading for suspected publication bias.
Reduced all-cause mortalityBAt 6 to 12 months, RR was 0.87 (95% CI 0.73 to 1.04) with moderate certainty, but the confidence interval included no effect, so a reduction was not established.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Cochrane systematic review and meta-analysis of randomized trials2,030Public and academic support including the UK Medical Research Council and Scottish Chief Scientist OfficeFatal or nonfatal myocardial infarction, all-cause admission, and all-cause mortalityAt 6 to 12 months, myocardial infarction RR was 0.72 (95% CI 0.55 to 0.93), high certainty; all-cause admission RR was 0.58 (0.43 to 0.77), moderate certainty; all-cause mortality RR was 0.87 (0.73 to 1.04), moderate certainty.Key endpoint-specific GRADE evidence
Study 2Contemporary meta-analysis of randomized trials in coronary heart disease12Public support from the UK Medical Research Council and Scottish Chief Scientist OfficeMyocardial infarction, hospitalisation, cardiovascular mortality, and all-cause mortalityAcross follow-up, myocardial infarction RR was 0.82 (95% CI 0.70 to 0.96), hospitalisation RR was 0.77 (0.67 to 0.89), and all-cause mortality RR was 0.96 (0.89 to 1.04).Cross-check of outcome direction
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-23).

Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;2021(11):CD001800. PMID: 34741536. PMCID: PMC8571912. DOI: 10.1002/14651858.CD001800.pub4.
checked
Dibben GO, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44(6):452-469. PMID: 36746187. PMCID: PMC9902155. DOI: 10.1093/eurheartj/ehac747.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none

Cite this verdict

Exercise-based cardiac rehabilitation x reduced recurrent myocardial infarction and hospitalisation in coronary heart disease Evidence Grade A card
[Chamgap] Exercise-based cardiac rehabilitation x reduced recurrent myocardial infarction and hospitalisation in coronary heart disease — Evidence Grade A·88. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/exercise-based-cardiac-rehabilitation-coronary-heart-disease-mi-hospitalisation/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.